Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07500922

Menopause Effects on Cortico-reticular Functioning

Post-menopausal women who request to begin hormone-replacement therapy (HRT) are directed to the research team. The participants are tested before beginning HRT, after two months of HRT, and five months of HRT. Tests include strength performance, central nervous system functioning, body composition, resting metabolic rate, and vascular screening. The participants are provided a 12-week training intervention (2 x strength, 2 x endurance per week) that can be voluntarily followed between tests at month 2 and 5. Compliance with the training program is recorded. A minimum of 15 participants are needed a priori, but the investigators aim to recruit and test 20 women.

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year–59 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Jyväskylä

Jyväskylä, 40014, Finland

Location status: Recruiting

Location contact

Simon Walker, PhD

CONTACT

[email protected]

+358408054906

About this study

Study aim: To determine cortico-reticular functioning during low and high female sex hormone, estrogen and progesterone, concentrations.

Hypothesis: Greater functioning/response during neurophysiological tests will occur in the presence of high compared to low estrogen concentrations accompanying greater force production capacity. In addition, pathways reliant on a greater number of synapses, i.e. cortico-reticulospinal, will demonstrate the greatest difference between hormone concentrations.

Justification: Several studies in monkeys and humans suggest that the methodology employed is sensitive to distinguish between high and low force production capacity. Estrogen is a neurotransmitter agonist exerting its influence at least via glutamate and GABA interneuron functioning, respectively.

The MENSA study is a locally administered trial where volunteers who request to be put on combined hormone replacement therapy will be recruited through cooperation with gynaecologists in the Jyväskylä area. Participants visit the University of Jyväskylä laboratories 1-5 days before beginning treatment (baseline), 2 months after beginning treatment and 5 months after beginning treatment having completed a 12-week non-supervised exercise intervention.

The experimental sessions will be conducted in the morning (beginning at approximately 7 am) following an overnight fast, and the time of the day kept constant for each individual participant (± 1 h). The posteriori measurement of serum follicular-stimulating hormone, estradiol and progesterone concentrations will be used to verify the hormonal status of the participants.

A recent study showed that a sample of 12-15 participants would be expected to lead to moderate-to-large (0.2-0.9) effect sizes in the tests of cortico-cortico and cortico-reticular functioning. The target muscle is the biceps brachii performing voluntary unilateral isometric elbow flexion actions. MENSA aims to recruit 20 females; this attempts to overcome potential reduced sample size through drop-out or measurement/technical error, as well as sufficiency for detection of possible changes in secondary outcome measures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • at least 6 months since their last period but no more than being 5 years post-menopausal
  • basal follicular-stimulating hormone concentration > 30 IU/L (confirmed post-recruitment)
  • willing to start combined hormonal treatment
  • womb and ovaries intact with normal functioning throughout reproductive age
  • willing to provide informed consent
  • does not have any of the exclusion criteria for TMS measurements according to Rossi et al. (2021 Clin Neurophysiol. 132(1):269-306.) (i.e. arterial hypertension, heart attack/seizure history, migraine, pacemaker or cochlear implant or other implanted metal/electronic device)

Exclusion criteria

  • classified as excessively obese via BMI assessment (i.e., >35 kg/m2)
  • intra-uterine device usage during transition to menopause
  • cardiovascular or skeletomuscular disease preventing strenuous physical activity
  • smoker
  • diagnosed psychiatric illness
  • epilepsy
  • other diagnosed injuries/illness affecting the neuromuscular system

Treatment and study plan

physical training

Behavioral

A 12-week, 4 x per week (2 x strength and 2 x endurance) training program to be performed voluntarily by the participants after tests at month 2.

Primary outcomes

  1. Short-interval intracortical inhibition (SICI)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Ten double-pulse transcranial magnetic stimulations delivered with 3 ms inter-stimulus interval. The conditioning pulse delivered at 80% of active motor threshold and the test pulse delivered at 120% of active motor threshold. Motor-evoked potential amplitude compared to single-pulse responses at 120% of active motor threshold.

Secondary outcomes

  1. Motor-evoked potential recruitment curve

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Ten transcranial magentic stimulations (single-pulse) at 100%, 120%, 140%, 160%, 180% and 200% of active motor threshold. Calculations of I50 and area-under-the-recruitment-curve to be performed offline.

  2. StartleTMS

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Twenty single-pulse transcranial magnetic stimulations delivered using 120% of active motor threshold. Ten stimulations without sound and ten stimulations conditioned by a loud sound (120 dB, 50 Hz) delivered 50 ms prior to TMS discharge.

  3. Intra-cortical facilitation (ICF)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Ten double-pulse transcranial magnetic stimulations delivered with 15 ms inter-stimulus interval. The conditioning pulse delivered at 80% of active motor threshold and the test pulse delivered at 120% of active motor threshold. Motor-evoked potential amplitude compared to single-pulse responses at 120% of active motor threshold.

  4. Long-interval intracortical inhibition (LICI)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Ten double-pulse transcranial magnetic stimulations delivered with 50 ms inter-stimulus interval. The conditioning pulse delivered at 120% of active motor threshold and the test pulse delivered at 120% of active motor threshold. Motor-evoked potential amplitude of the test pulse compared to the amplitude of the conditioning pulse.

  5. Motor-evoked potential to anterior-posterior current

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    The TMS coil is rotated 180 degrees to induce the opposite direction current within the cortex. A new active motor threshold for this coil orientation is first attained and then ten stimulations with 120% and 140% of active motor threshold are delivered. Motor-evoked potential amplitude is analysed offline.

  6. StartReact

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Reaction test where the participant contracts the biceps brachii upon seeing a flashing white LED light 1 m in front. Ten flashes occur without accompanying sound. Ten flashes occur accompanied by a quiet sound (80 dB, 50 Hz). Ten flashes occur accompanied by a loud sound (120 dB, 50 Hz). The order of the conditions presented is randomized and separated by approximately 8 s. Reaction time is analysed from the presentations of the flash to the beginning (7 SD above baseline) of the voluntary electromyogram burst. The difference in the reactions times between conditions are calculated. Further analyses regarding rate of force development and voluntary EMG amplitude over 0-50 ms from each contraction are assessed.

  7. Maximum isometric voluntary contraction (MVC)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Testing is performed under controlled pre-test conditions (10-12 h fast, no vigorous physical activity in the prior 24 h), seated in a thermoneutral room. The participant performs 3-5 isometric elbow flexion actions by maximally contracting the biceps brachii muscle while seated in an electromechanical dynamometer. Force and electromyography (EMG) activity are recorded during the contractions.

  8. Resting energy expenditure (i.e. resting metabolic rate)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Measured by Indirect Calorimetry Resting energy expenditure (REE) is measured by indirect calorimetry (ventilated hood; overnight fast 10-12 h; supine, thermoneutral room). After stabilization, VO2 and VCO2 are recorded for ≥20-30 min; a steady-state segment (e.g., ≥5 min with CV <10% and physiologic RQ) is used to compute REE (kcal/day) via the Weir equation, higher values

    = higher energy expenditure. Outcome is change from baseline to follow-up (follow-up - baseline); higher positive values = higher increase in energy expenditure. Procedures/quality criteria follow the device manual and the Statistical Analysis Plan (SAP). Per SAP, supportive analyses may adjust for body composition (FFM/FM) or express REE relative to FFM; these do not replace the prespecified analysis of this primary outcome.

  9. Total fat mass

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Total fat mass (FM) will be measured by bioelectrical impedance analysis (BIA; InBody) under standardized conditions, including a 10-12 h fast before assessment. FM is reported in kg; higher values indicate higher fat mass. The outcome is the change from baseline to the specified follow-up (follow-up - baseline).

  10. Fat-free mass

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Fat-free mass (FFM) will be measured by bioelectrical impedance analysis (BIA; InBody) under standardized conditions, including a 10-12 h fast before assessment. FFM is reported in kg; higher values indicate higher fat-free mass.

  11. Aotic pulse wave velocity

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Aortic pulse wave velocity (PWV) will be measured using an oscillometric Arteriograph device under standardized resting conditions, including a 10-12 h fast and avoidance of vigorous physical activity during the previous 24 h.

    Measurements are taken supine in a quiet, thermoneutral room. PWV is reported in m/s; higher values indicate greater arterial stiffness.

  12. Arterial wave reflection

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Augmentation Index (AIx) will be measured using the Arteriograph under the same standardized resting conditions, including a 10-12 h fast and avoidance of vigorous physical activity during the preceding 24 h. AIx is expressed in %; higher values indicate greater arterial wave reflection.

  13. Reflection time

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Reflection time measured by Arteriograph in standardized rest (as above). ms; shorter RT = faster wave return.

  14. Microvascular perfusion

    Time frame: Change from baseline to month 2 and baseline to month 5

    Resting cutaneous microvascular perfusion measured at the forearm using Laser Doppler under standardized resting conditions (10-12 h fast, no vigorous physical activity in prior 24 h, supine, thermoneutral). Perfusion units (PU); higher = higher resting microvascular flow.

  15. Endothelium-Dependent Vasodilation (Laser Doppler, %)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Endothelium-dependent vasodilatory response measured at the forearm using Laser Doppler during standardized forearm occlusion to induce a controlled ischemic stimulus under resting conditions (as above). % change from baseline; higher = better endothelial function.

  16. Post-Occlusive Reactive Hyperemia (PORH, %)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Post-occlusive reactive hyperemia measured at the forearm with Laser Doppler under standardized rest (as above). % increase; higher = better microvascular reactivity.

  17. Resting Near-Infrared Spectroscopy (NIRS) Tissue Oxygen Saturation (StO2, %)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    Near-Infrared Spectroscopy (NIRS)-derived quadriceps StO2 at rest under standardized conditions (10-12 h fast, no vigorous PA in prior 24 h, supine, thermoneutral). %; higher = higher oxygenation.

  18. Near-Infrared Spectroscopy (NIRS) Total Hemoglobin (tHb, au)

    Time frame: Change from baseline to month 2 and change from baseline to month 5

    NIRS-derived tHb signal (during rest). Arbitrary units; marker of local microvascular blood volume.

Study contacts

Contact information is provided by the study sponsor or research team.

Simon Walker Dr (Dos.), PhD

CONTACT

[email protected]

+358408054906

Sponsors and collaborators

Lead sponsor

University of Jyvaskyla

Other

Registry information

Official study title

Female Sex Hormone and Menopause Effects on Cortico-reticular Functioning

Acronym: MENSA

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Mar 30, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.